Eli Lilly and Co
LLY
Company Profile
Business description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Contact
Lilly Corporate Center
IndianapolisIN46285
USAT: +1 317 276-2000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2024
Employees
43,000
Eli Lilly and Co News & Analysis
stocks
What broadening rally? AI stocks dominate US market again in Q2
Nvidia, Apple, and other major AI players drove market performance to an even greater degree in the quarter.
video
Will obesity drugs derail ResMed?
Morningstar analyst Shane Ponraj discusses the latest clinical trial results from Eli Lilly.
stocks
Obesity drug stocks: Why it will be ‘exceptionally difficult’ to dethrone Eli Lilly and Novo Nordisk
The two biggest players in the market appear poised to dominate for years to come.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,622.00 | 55.00 | 0.64% |
| CAC 40 | 7,213.32 | 14.87 | 0.21% |
| DAX 40 | 19,146.17 | 141.39 | 0.74% |
| Dow JONES (US) | 43,870.35 | 461.88 | 1.06% |
| FTSE 100 | 8,149.27 | 64.20 | 0.79% |
| HKSE | 19,601.11 | 103.90 | -0.53% |
| NASDAQ | 18,972.42 | 6.28 | 0.03% |
| Nikkei 225 | 38,026.17 | 326.17 | -0.85% |
| NZX 50 Index | 12,906.95 | 141.71 | 1.11% |
| S&P 500 | 5,948.71 | 31.60 | 0.53% |
| S&P/ASX 200 | 8,382.10 | 59.10 | 0.71% |
| SSE Composite Index | 3,370.40 | 2.41 | 0.07% |